Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

o A Prospective, Randomized, Open-Label, Phase II Study Evaluating the Efficacy of Tadalafil for the Prevention of Docetaxel-Induced Peripheral Neuropathy in Patients With Metastatic Prostate Cancer

NCT07333976 is registered in ClinicalTrials.gov with Tri-Service General Hospital (TSGH) as lead sponsor.

NCT NCT07333976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07333976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
o A Prospective, Randomized, Open-Label, Phase II Study Evaluating the Efficacy of Tadalafil for the Prevention of Docetaxel-Induced Peripheral Neuropathy in Patients With Metastatic Prostate Cancer
Lead sponsor
Tri-Service General Hospital (TSGH)
Phase
Phase 2
Overall status
Completed
Start date
January 5, 2020
Completion date
August 13, 2024
Enrollment
90 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy induced peripheral neuropathy (cipn), neurotoxicity, prostate cancer metastatic disease